<scp>CT</scp> ‐ <scp>P39</scp> Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study
Sarbjit S. Saini(Johns Hopkins University), Clive Grattan(Guy's Hospital), Ewa Springer, Yevgeniya Dytyatkovska, Grażyna Pulka(Jagiellonian University), Adam Reich(Rzeszów University of Technology), Chun Wook Park(Hallym University Kangnam Sacred Heart Hospital), Marta Chełmińska(Gdańsk Medical University), Marcus Maurer(Humboldt-Universität zu Berlin), Sung-Hyun Kim(Celltrion (South Korea)), Jong‐Ho Kim(Korea University), Sewon Lee(Celltrion (South Korea)), Su‐Young Kim(Celltrion (South Korea)), Keumyoung Ahn(Celltrion (South Korea)), Jochheim Ka(Celltrion (South Korea)), Maria Ratkova, Borislava Krusheva(Medical University of Sofia)
Cited by 28
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892